A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Andrea WANG-GILLAM; Stacey PLAMBECK-SUESS; Benjamin Tan; Williams G Hawkins; Peter Goedegebuure; Peter O Simon; Jonathan B Mitchem; John R Hornick; Steven Sorscher; Joel Picus; Rama Suresh; Albert C Lockhart

doi:10.1007/s10637-012-9866-y

Back

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Journal article

Open access

Peer reviewed

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Andrea WANG-GILLAM, Stacey PLAMBECK-SUESS, Benjamin Tan, Williams G Hawkins, Peter Goedegebuure, Peter O Simon, Jonathan B Mitchem, John R Hornick, Steven Sorscher, Joel Picus, …

Investigational new drugs, Vol.31(3), pp.707-713

2013

DOI: https://doi.org/10.1007/s10637-012-9866-y

PMCID: PMC3760728

PMID: 22864469

Abstract

Biological and medical sciences

Gastroenterology. Liver. Pancreas. Abdomen

Liver. Biliary tract. Portal circulation. Exocrine pancreas

Medical sciences

Multiple tumors. Solid tumors. Tumors in childhood (general aspects)

Tumors

Files and links (1)

url

https://doi.org/10.1007/s10637-012-9866-yView

Published (Version of record) Open

Metrics

5 Record Views

73 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.214 PD-1
Web Of Science research areas: Oncology; Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Creators: Andrea WANG-GILLAM - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Stacey PLAMBECK-SUESS - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Benjamin Tan - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Williams G Hawkins - Siteman Cancer Center, St. Louis, MO, United States
Peter Goedegebuure - Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States
Peter O Simon - Vascular and Interventional Radiology, University of Virginia Health System, Charlottesville, VA, United States
Jonathan B Mitchem - Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States
John R Hornick - Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States
Steven Sorscher - Siteman Cancer Center, St. Louis, MO, United States
Joel Picus - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Rama Suresh - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Albert C Lockhart - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Publication Details: Investigational new drugs, Vol.31(3), pp.707-713
Publisher: Springer
Academic Unit: Miller School of Medicine
Language: English
Resource Type: Journal article
PMID: 22864469
PMCID: PMC3760728
Record Identifier: 991031614957102976